Clinical Trial Update: Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Inclisiran's effect on LDL-C in patients with heterozygous familial hypercholesterolemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: The Medicines Company | Conditions: Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol | Phase 3 | Status: COMPLETED | Results posted: 2020-10-28